Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2030

Posted on
by

Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast - 2030

DelveInsight has launched a new report on Merkel Cell Carcinoma Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Merkel Cell Carcinoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Merkel Cell Carcinoma , historical and forecasted epidemiology as well as the Merkel Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Merkel Cell Carcinoma market report provides current treatment practices, emerging drugs, Merkel Cell Carcinoma market share of the individual therapies, current and forecasted Merkel Cell Carcinoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Merkel Cell Carcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Merkel Cell Carcinoma (MCC) is a rare, highly aggressive neuroendocrine cutaneous neoplasm with a variable clinical presentation. It is a predominantly dermal-based lesion composed of monotonous small round cells with scanty cytoplasm, often difficult to differentiate from small round cell tumors, metastatic small cell carcinoma, blastic hematologic malignancies, and melanoma.
 
 
Request for :- free sample page
 
Epidemiology
The Merkel Cell Carcinoma epidemiology division provide insights about historical and current Merkel Cell Carcinoma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
 
Report key facts:- 
 
1. As per “Skin Cancer Foundation”, Merkel cell carcinoma (MCC) is 40 times more rare than melanoma, with an estimated one case per 130,000 people in the US.
 
 
2. According to a study in Germany, the incidence rate of MCC is 0.30 (women) and 0.40 (men) (1988–2010) and in Eastern France the incidence rate is 0.13 (1980–2004) (Dirk Schadendorf et al.)

3.  As per study conducted by João Pedreira Duprat, et al. (2011), The estimated annual incidence of MCC is 0.23 per 100,000 individuals for Caucasians, whereas the incidence in those of African descent is 0.01 per 100,000 and appears to be even lower in Polynesians.

In most people, the first sign of Merkel cell carcinoma is a small bump (nodule) on the skin. This bump is usually firm and appears either skin-colored or red-purple. It also tends to grow rapidly. Often, there no symptoms associated with the nodule
 
Key major companies are working on MCC that are given below:- 
 

1. Merck Pharma Co.
2. Incvte Corporation
3. Kartos Therapeutics

Name of covered drugs that are given below:-
 

1. Avelumab
2. Pembrolizumab
3. INCMGA00012

Table of contents

1. Key Insights

2. Executive Summary of Merkel Cell Carcinoma

3. Competitive Intelligence Analysis for Merkel Cell Carcinoma

4. Merkel Cell Carcinoma : Market Overview at a Glance

4.1. Merkel Cell Carcinoma Total Market Share (%) Distribution in 2017

4.2. Merkel Cell Carcinoma Total Market Share (%) Distribution in 2030

5. Merkel Cell Carcinoma : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Merkel Cell Carcinoma Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Merkel Cell Carcinoma Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Merkel Cell Carcinoma Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Merkel Cell Carcinoma Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Merkel Cell Carcinoma Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Merkel Cell Carcinoma Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Merkel Cell Carcinoma Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Merkel Cell Carcinoma Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Merkel Cell Carcinoma Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Merkel Cell Carcinoma Treatment and Management

8.2. Merkel Cell Carcinoma Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Merkel Cell Carcinoma Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Merkel Cell Carcinoma : Seven Major Market Analysis

13.1. Key Findings

13.2. Merkel Cell Carcinoma Market Size in 7MM

13.3. Merkel Cell Carcinoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Merkel Cell Carcinoma Total Market Size in the United States

15.1.2. Merkel Cell Carcinoma Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Merkel Cell Carcinoma Total Market Size in Germany

15.3.2. Merkel Cell Carcinoma Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Merkel Cell Carcinoma Total Market Size in France

15.4.2. Merkel Cell Carcinoma Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Merkel Cell Carcinoma Total Market Size in Italy

15.5.2. Merkel Cell Carcinoma Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Merkel Cell Carcinoma Total Market Size in Spain

15.6.2. Merkel Cell Carcinoma Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Merkel Cell Carcinoma Total Market Size in the United Kingdom

15.7.2. Merkel Cell Carcinoma Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Merkel Cell Carcinoma Total Market Size in Japan

15.8.3. Merkel Cell Carcinoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Merkel Cell Carcinoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Merkel Cell Carcinoma market
  • To understand the future market competition in the Merkel Cell Carcinoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Merkel Cell Carcinoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Merkel Cell Carcinoma market
  • To understand the future market competition in the Merkel Cell Carcinoma market

Related Reports:-

1. Merkel Cell Carcinoma – Pipeline Insights, 2020

2. Merkel Cell Carcinoma – Epidemiology Forecast to 2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/